This phase II study was designed to evaluate the efficacy and safety of the pan-HDAC inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin for the treatment of advanced recurrent, platinum-sensitive ovarian cancer. Here, HDAC9 is linked to ovarian carcinoma.